Skip to content
Visit us at ASCO22 | June 3-7 | Booth #16113
Get expert insights on spatial biology & local attractions
Flagship Biosciences
  • About
    • Process
    • Technology
    • Company
    • Our Vision
    • Careers
  • Pharma
    • Image Analysis
    • IHC Assays / IF Assays / ISH Assays
      • Assay Solutions Listing
    • Multiplex Assays
    • Data Analysis and Reporting
    • Consultation with Scientific Experts
    • Regulatory Strategy and Support
  • CDx Development
  • Clinical Diagnostics
    • Clinical Data
    • Approved Partner Program
    • Scientific Advisory Board
  • Resources
    • News
    • Blog
    • Events
    • Posters & Publications
    • Collateral
  • Contact Us

POSTERS & PUBLICATIONS

Macrophage Biomarkers CD68 and CD163 Correlate with NSCLC Patient Survival (Poster No. 1720 at #AACR2022)

Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates

Read More »
May 5, 2022

Macrophage Biomarkers CD68 and CD163 Correlate with CRC Patient Survival (Poster No. 2530 at #AACR2022)

Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’

Read More »
May 5, 2022

Virtual Centralized Pathology = More Accurate Patient Data (Poster No. 10018 at Digital Pathology Association’s Pathology Visions 2021 #pathvisions21)

Background Historically, immunohistochemistry (IHC) assays have been designed for simplicity of manual pathology, however, this is not always ideal to acquire the appropriate data for

Read More »
October 18, 2021

Original Research Article (Pfizer): First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7 (PTK7), in Advanced Solid Tumors

In the downloadable original research article sponsored by Pfizer, the digital tissue analysis was performed using the Flagship Biosciences proprietary Image Analysis platform. The article

Read More »
September 2, 2021

Original Research Article: Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors

In partnership with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, Flagship Biosciences published this downloadable original research article. It was

Read More »
September 1, 2021

Clinical Validation of a Dickkopf-1 (DKK1) Chromogenic In-situ Hybridization (CISH) Assay for Manual and Image Analysis Assisted Pathologist Interpretation (Poster No. 433 #AACR2021 in partnership with Leap Therapeutics)

Background Dickkopf-1 (DKK1) is a secreted modulator of Wnt signaling that is frequently overexpressed in tumors and associated with a poor prognosis. In this study,

Read More »
April 8, 2021
⟨ Page1 Page2 Page3 Page4 Page5 ⟩

Sign up to receive
industry and company
news, including
The Cut Point,
Flagship’s quarterly
e-newsletter.





Recent Posts

  • Recognizing women leaders in biotechnology
  • Flagship Spotlight: Jordyn Vincelet – Sales Coordinator at Flagship Biosciences
  • Tissue Based Companion Diagnostics in a Regulated Space
  • Flagship Spotlight: Roberto Gianani, MD
  • Flagship Spotlight: Adam Beharry

Resources

  • News
  • Blog
  • Events
  • Posters & Publications
  • Collateral

READY TO TAKE THE NEXT STEP?

Start Your Consultation Today

Our Services

Pharma

Cell-based image analysis, assays, and partnership to advance clinical trials and regulatory acceptance.

Learn More

Clinical Diagnostics

Dependable clinical diagnostic testing to connect patients to individualized, immuno-oncology therapies.

Learn More

Related Resources

Blog

Posters & Publications

News

Flagship carefully tracks our tissue to ensure we can analyze every assay and stay on schedule.
Sr. Pharmaceutical Research Director
Sr. Pharmaceutical Research Director
We are trying to bridge from the discovery stage to clinical development. Flagship's pathologists and scientists provide critical input and the company helps us organize and analyze an incredible amount of data. I highly recommend Flagship for its expertise and support for drug development projects.
Biopharma Director
Biopharma Director
During clinical trials, I interact with our manufacturing, legal, pre-clinical, and biomarker teams. Our Flagship project manager understands our tight timeline and ensures delivery of the data we need, when we need it.
Biotech Pharmaceutical Operations Director
Biotech Pharmaceutical Operations Director
We are pleased to partner with Flagship Biosciences to integrate their machine learning/AI tools to provide cancer marker detection.
Laboratory Software Solutions Provider COO
Flagship’s image analysis experts are flexible and willing to work with us to develop projects that meet the changing needs of our clinical trials drug development.
Sr. Pharmaceutical Research Director
Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities.
Global Oncology Research Database Provider CEO
The ease of leveraging Flagship’s powerful solution is yet another massive differentiator of the company. Clients need not have to change their existing workflows, investments in technology, or even the assays that they use.
CIO Review, Pharma and Life Sciences

About Flagship Biosciences

We are a multi-disciplinary team of pathologists, biologists, analysts, software engineers, and technicians who are committed to creating successful approaches which match patients with life-saving drugs.
Learn More >

CAP and CLIA logos

Quick Links

  • Pharma
  • CDx Development
  • Clinical Diagnostics
  • Posters & Publications
  • Events
  • Careers
  • Contact Us
Menu
  • Pharma
  • CDx Development
  • Clinical Diagnostics
  • Posters & Publications
  • Events
  • Careers
  • Contact Us

Connect With Us

Linkedin Facebook Twitter Envelope

11800 Ridge Parkway, Suite 450
Broomfield, CO 80021
303.325.5894

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.



 
 


  • Copyright 2022 Flagship Biosciences Inc.
  • Privacy Policy
  • 11800 Ridge Parkway, Suite 450, Broomfield, CO 80021
Search for:
Close Menu
Manage Cookie Consent
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of all cookies.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
Preferences
{title} {title} {title}



×



×



×

Start Your Consultation Today